Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 2/2004

01-04-2004 | Commentary

Measuring effectiveness of drugs in observational databanks: promises and perils

Authors: Eswar Krishnan, James F Fries

Published in: Arthritis Research & Therapy | Issue 2/2004

Login to get access

Abstract

Observational databanks have inherent strengths and shortcomings. As in randomized controlled trials, poor design of these databanks can either exaggerate or reduce estimates of drug effectiveness and can limit generalizability. This commentary highlights selected aspects of study design, data collection and statistical analysis that can help overcome many of these inadequacies. An international metaRegister and a formal mechanism for standardizing and sharing drug data could help improve the utility of databanks. Medical journals have a vital role in enforcing a quality checklist that improves reporting.
Literature
1.
Menard HA, Beaudet F, Davis P, Harth M, Percy JS, Russell AS, Thompson JM: Gold therapy in rheumatoid arthritis. Interim report of the Canadian multicenter prospective trial comparing sodium aurothiomalate and auranofin. J Rheumatol Suppl. 1982, 8: 179-183.PubMed
2.
Bombardier C, Ware J, Russell IJ, Larson M, Chalmers A, Read JL: Auranofin therapy and quality of life in patients with rheumatoid arthritis. Results of a multicenter trial. Am J Med. 1986, 81: 565-578. 10.1016/0002-9343(86)90539-5.CrossRefPubMed
3.
Pincus T: Limitations of randomized clinical trials to recognize possible advantages of combination therapies in rheumatic diseases. Semin Arthritis Rheum. 1993, 23 (2 Suppl 1): 2-10.CrossRefPubMed
4.
Felson DT, Anderson JJ, Meenan RF: The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum. 1990, 33: 1449-1461.CrossRefPubMed
5.
Anon: Epidemiology and randomized clinical trials [editorial]. Epidemiology. 2003, 14: 2-10.1097/00001648-200301000-00002.CrossRef
6.
Krishnan E, Fries JF: Reduction in long-term functional disability in rheumatoid arthritis from 1977 to 1998: a longitudinal study of 3035 patients. Am J Med. 2003, 115: 371-376. 10.1016/S0002-9343(03)00397-8.CrossRefPubMed
7.
8.
Wolfe F, Lassere M, van der Heijde D, Stucki G, Suarez-Almazor M, Pincus T, Eberhardt K, Kvien TK, Symmons D, Silman A, van Riel P, Tugwell P, Boers M: Preliminary core set of domains and reporting requirements for longitudinal observational studies in rheumatology. J Rheumatol. 1999, 26: 484-489.PubMed
9.
Silman A, Symmons D: Reporting requirements for longitudinal observational studies in rheumatology. J Rheumatol. 1999, 26: 481-483.PubMed
10.
11.
Wolfe F, Pincus T: Listening to the patient: a practical guide to self-report questionnaires in clinical care. Arthritis Rheum. 1999, 42: 1797-1808. 10.1002/1529-0131(199909)42:9<1797::AID-ANR2>3.0.CO;2-Q.CrossRefPubMed
12.
Fries JF, Williams CA, Singh G, Ramey DR: Response to therapy in rheumatoid arthritis is influenced by immediately prior therapy. J Rheumatol. 1997, 24: 838-844.PubMed
13.
Moses LE: Measuring effects without randomized trials? Options, problems, challenges. Med Care. 1995, 33 (4 Suppl): AS8-AS14.PubMed
14.
Rennie D: How to report randomized controlled trials. The CONSORT statement [editorial]. JAMA. 1996, 276: 649-10.1001/jama.276.8.649.CrossRefPubMed
Metadata
Title
Measuring effectiveness of drugs in observational databanks: promises and perils
Authors
Eswar Krishnan
James F Fries
Publication date
01-04-2004
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 2/2004
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar1151

Other articles of this Issue 2/2004

Arthritis Research & Therapy 2/2004 Go to the issue

Viewpoint

Hypoxia: not merely a regulator of angiogenesis?

Research article

Giantin is the major Golgi autoantigen in human anti-Golgi complex sera

Research article

IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-κB- and PI3-kinase/Akt-dependent pathways

Research article

Serum levels of autoantibodies against monomeric C-reactive protein are correlated with disease activity in systemic lupus erythematosus

Review

Towards in vivoapplication of RNA interference – new toys, old problems

Meeting report

Kennedy Institute of Rheumatology Division, Imperial College London, 12–13 November 2003: Towards a molecular toolkit for studying lymphocyte function in inflammatory arthritis

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits